Drug intelligence / Profile preview

spyk04

Development stage: Phase 1
Lead developer: Chugai Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

SPYK04 is an oral small molecule drug that was developed by Chugai Pharmaceutical for the treatment of solid tumors with specific gene mutations. It was investigated in a phase I open-label, multicenter dose escalation and cohort expansion study in patients with locally advanced or metastatic solid tumors harboring RAS gene mutations. The drug was administered as a capsule taken orally once daily. The primary aim of clinical development was to assess safety and pharmacokinetics in this patient population. Development has been discontinued[1][3][4].

Other names: spyk04spyk-04spyk 04

Targets

ARAF (Proto-oncogene serine/threonine-protein kinase A-Raf)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)

Beyond the preview

Go deeper on spyk04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on spyk04.

Explore the full profile